The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 26, 2024

Filed:

Mar. 19, 2020
Applicant:

Voronoi Inc., Incheon, KR;

Inventors:

Youn Ho Lee, Incheon, KR;

Ju Hee Kang, Incheon, KR;

Se In Kang, Incheon, KR;

Yi Kyung Ko, Incheon, KR;

Eun Hwa Ko, Incheon, KR;

Hwan Geun Choi, Seoul, KR;

Jung Beom Son, Incheon, KR;

Nam Doo Kim, Incheon, KR;

Assignee:

VORONOI INC., Incheon, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 413/14 (2006.01); A61K 31/407 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/5386 (2006.01); A61P 35/00 (2006.01); C07D 409/14 (2006.01); C07D 413/04 (2006.01); C07D 417/04 (2006.01); C07D 471/04 (2006.01); C07D 471/18 (2006.01); C07D 487/04 (2006.01); C07D 487/08 (2006.01); C07D 491/048 (2006.01); C07D 491/08 (2006.01); C07D 491/107 (2006.01); C07D 498/08 (2006.01);
U.S. Cl.
CPC ...
C07D 413/14 (2013.01); A61P 35/00 (2018.01); C07D 413/04 (2013.01); C07D 487/08 (2013.01); C07D 498/08 (2013.01);
Abstract

The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.


Find Patent Forward Citations

Loading…